Supreme Pharmaceuticals Inc. (“Supreme” or the “Company“) (TSXV: FIRE) is pleased to announce that it has retained Bayfield Strategy, Inc. (“Bayfield”) to provide comprehensive Investor and Public Relations. Bayfield will work with Supreme’s leadership team to achieve its broad communications goals to support growth with a focus on expanding capital markets awareness and enhance engagement with shareholders and stakeholders.
“Supreme, through its wholly-owned subsidiary 7ACRES, is committed to producing high quality cannabis at scale. Our focus to date has been developing a core competency and proprietary value in cultivation, building out our state-of-the-art Hybrid Greenhouse facility, raising capital to fund growth and graduating to the TSX Venture. Having now achieved a significant milestone, moving into revenue and undergoing significant expansion, we believe Bayfield will be a strong partner for disseminating our story to a broader investor audience and the management of our existing stakeholders. We believe Bayfield’s unique offering of investor relations, public relations and government relations is an ideal combination for a public company in the highly regulated nascent cannabis industry in Canada, ” said John Fowler, CEO of Supreme.
For Investor Relations, please contact:
Bayfield Strategy, Inc.
Supreme is a Canadian publicly traded company committed to becoming a leading cultivator and distributor of sun grown cannabis through its wholly owned subsidiary 7ACRES. 7ACRES is a federally licensed producer of medical cannabis pursuant to the ACMPR operating inside a 342,000 sq. ft. Hybrid Greenhouse facility. The Hybrid Greenhouse combines the best technology of indoor production with the efficiencies and sustainability of a greenhouse, in a single large-format production footprint. Please visit www.supreme.ca and www.7acres.com for more information.
Bayfield Strategy, Inc. is leading financial communications firm that represents public companies, private equity firms, hedge funds and high-profile individuals in mandates across Canada, the United States, Europe and the United Kingdom.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Supreme Pharmaceuticals Inc.